Metabolic dysfunction associated steatohepatitis (MASH)
Clinical trials for Metabolic dysfunction associated steatohepatitis (MASH) explained in plain language.
Never miss a new study
Get alerted when new Metabolic dysfunction associated steatohepatitis (MASH) trials appear
Sign up with your email to follow new studies for Metabolic dysfunction associated steatohepatitis (MASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Navy beans take on fatty liver: a diet swap put to the test
Disease control Not yet recruitingThis trial tests whether replacing some of the usual diet with navy beans — without changing total calories — is a practical and acceptable way to help manage metabolic dysfunction-associated steatotic liver disease (MASLD) in adults with intermediate-stage liver fibrosis. Forty …
Matched conditions: METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Could a tailored diet make a MASH drug work better?
Disease control Not yet recruitingThis study tests whether adding a Mediterranean-style meal delivery program to resmetirom therapy improves liver health more than resmetirom alone. It involves 120 adults with non-cirrhotic MASH who are starting resmetirom. Participants either receive the drug plus 10 medically t…
Matched conditions: METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
Phase 4 • Sponsor: City University of New York • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug aims to melt liver fat and stop scarring in MASH patients
Disease control Not yet recruitingThis study tests an experimental drug called ALN-CIDEB in 150 adults with MASH, a serious liver disease involving fat buildup and scarring. The goal is to see if the drug can reduce liver fat, injury, and scarring compared to a placebo. Participants will receive either the drug o…
Matched conditions: METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
Phase 2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New shot aims to reverse liver scarring in MASH patients
Disease control Not yet recruitingThis Phase 2 trial tests a new drug called QL2401 in 132 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate liver scarring. Participants receive weekly injections of either QL2401 or a placebo for 48 weeks. The main goal is to see if the drug reduces…
Matched conditions: METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
Phase 2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC